Conventional DAPT
Phase 3Small molecule
Conventional DAPT is one of 55 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
114 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Brilinta
AstraZenecaApproved
Crestor
AstraZenecaApproved
Corlanor
AmgenApproved
Ozempic
Novo NordiskApproved
Niacor
AbbVieApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Glucophage
EMD SeronoApproved
Cardizem
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Conventional DAPT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZunyi Medical College